(Q35872802)

10 August 2017

1 reference

title

Systematic review of bisphosphonates for hypercalcaemia of malignancy (English)

1 reference

10 August 2017

1 reference

Y Saunders

1

1 reference

10 August 2017

J R Ross

2

1 reference

10 August 2017

K E Broadley

3

1 reference

10 August 2017

P M Edmonds

4

1 reference

10 August 2017

S Patel

5

1 reference

10 August 2017

Steering Group

6

1 reference

10 August 2017

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

18

1 reference

10 August 2017

418-431

1 reference

10 August 2017

5

1 reference

Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate

10 August 2017

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Variation in Plasma Calcium with Induced Changes in Plasma Specific Gravity, Total Protein, and Albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Interpretation of serum calcium in patients with abnormal serum proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Management of acute hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Acute management of cancer-related hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Salmon calcitonin in the acute management of hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Somatostatin analogue treatment for malignant hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

The pharmacology of bisphosphonates and new insights into their mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Molecular mechanisms of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0269216304PM914RA

10.1191/0269216304PM914RA

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference